Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
0 hedge funds and large institutions have $0 invested in Achilles Therapeutics in 2026 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $98.9K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Trium Capital
London,
United Kingdom
|
-$91K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$6.63K |
| 3 |
GAMMA Investing
Foster City,
California
|
-$1.19K |
ACHL Hedge Fund Activity: Q3 2026 in Review
0 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q3 2026, worth a combined $0 — down 100% from $98.9K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ACHL and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Trium Capital, exiting entirely with an estimated $91K sold.
- 0 institutional investors held Achilles Therapeutics (ACHL) as of Q3 2026, down from 3 in Q2 2026.
- Funds reported $0 of Achilles Therapeutics stock for Q3 2026, down 100% quarter-over-quarter.
- 0 funds opened new Achilles Therapeutics positions in Q3 2026 and 3 closed out, a net change of -3 holders.
- The largest Achilles Therapeutics seller in Q3 2026 was Trium Capital, an estimated $91K sold.
Based on aggregated 13F filings for Q3 2026.